Oxymetazoline 0.05% nasal spray

BACKGROUND: Since there is currently no conclusion on the efficacy and adverse effects of oxymetazoline, this meta-analysis attempts to explore its efficacy and adverse events, so as to provide guidance for clinical medication. METHODS: We searched PubMed, Embase, and Cochrane Library from the establishment of the database to May 2021. We included studies that patients were randomly assigned to receive oxymetazoline or vehicle, and we excluded duplicate publications, research without full text, incomplete information or inability to conduct data extraction, animal experiments, reviews, and systematic reviews. STATA 15.1 was used to analyze the data. RESULTS: The pooled results show that the 3 (RR = 1.76, 95% CI: 1.53-2.03), 6 (RR = 1.71, 95% CI: 1.47-2.00), 9 (RR = 1.63, 95% CI: 1.40-1.90), 12 (RR = 1.41, 95% CI: 1.18-1.67) -hours CEA success rate and the 3 (RR = 1.65, 95% CI: 1.34-2.03), 6 (RR = 1.75, 95% CI: 1.43-2.14), 9 (RR = 1.63, 95% CI: 1.33-2.00), 12 (RR = 1.78, 95% CI: 1.45-2.18) -hours SSA success rate after oxymetazoline treatment for rosacea is significantly higher than that of vehicle. Additionally, the pooled results show that the incidence of TEAEs after treatment with oxymetazoline is significantly higher than that of vehicle (RR = 1.34, 95% CI: 1.10-1.2). However, our analysis of specific adverse events found that the oxymetazoline group was only significantly higher than the vehicle group in the incidence of application-site dermatitis (RR = 8.91, 95% CI: 1.76-45.23), and there was no statistical significance in the difference in the incidence of other adverse events. CONCLUSION: Oxymetazoline is effective and can be selected for the treatment of persistent facial erythema of rosacea. Additionally, application-site dermatitis was the most important one.

Abstract licence: CC BY

Topical interventions for rosacea are often used to relieve local symptoms. However, currently, there are few articles to systematically analyze the efficacy profile of topical drugs for rosacea. This study aimed to investigate the efficacy profile of widely used topical drugs. To acquire appropriate information from related literature, we looked into 4 databases. Efficacy was appraised with the Investigator Global Assessment, Clinician's Erythema Assessment, Patient's Self-Assessment and Subject Self-Assessment of Rosacea Facial Redness scales. Treatment-emergent adverse events and dermal tolerability were also recorded. According to 21 randomized controlled trials included, a total of 6 topical drugs including minocycline, ivermectin, azelaic acid, metronidazole, brimonidine and oxymetazoline were reported. These drugs are well-tolerated and safe. Ivermectin is more effective than azelaic acid and metronidazole. Azelaic acid has a better efficacy profile than metronidazole according to included studies. Minocycline turned out to be effective improving the symptoms of rosacea. Brimonidine and oxymetazoline both have significant effects on reducing facial redness. La intervención local de la rosácea se utiliza generalmente para aliviar los síntomas locales. Sin embargo, hasta ahora, pocos artículos han analizado sistemáticamente la eficacia de los medicamentos locales en el tratamiento de la rosácea. El objetivo de este estudio es investigar la eficacia de los medicamentos locales de uso común. Para obtener la información adecuada de la literatura relevante, recuperamos cuatro bases de datos. La eficacia se evalúa mediante la evaluación general del investigador, la evaluación del eritema del clínico, la autoevaluación del paciente y la autoevaluación de la escala de enrojecimiento facial por rosácea del sujeto. También se registraron eventos adversos y tolerancia cutánea durante el tratamiento. Según los 21 ensayos aleatorizados controlados incluidos, hay seis fármacos tópicos: minociclina, ivermectina, ácido azelaico, metronidazol, bromonidina e hidroximetazolina. Estos medicamentos tienen una buena tolerancia y seguridad. La ivermectina es más eficaz que el ácido azelaico y el metronidazol. Según el estudio incluido, el ácido azelaico es mejor que el metronidazol. La minociclina puede mejorar eficazmente los síntomas de la rosácea. Tanto la bromonidina como la hidroximetazolina tienen un efecto significativo en la reducción del enrojecimiento facial.

Abstract licence: CC BY-NC-ND

Objective Oxymetazoline hydrochloride has been shown to be effective in some studies for acquired blepharoptosis and for aesthetic upper eyelid elevation. This study aims to systematically review the literature on the use of topical oxymetazoline for treating acquired blepharoptosis. Databases Reviewed PubMed (U.S. National Library of Medicine, National Institutes of Health), Scopus (Elsevier), and Cochrane. Methods A systematic review of studies published between 2013 and 2024 following PRISMA guidelines was performed using the PubMed, Scopus, and Cochrane databases. Primary outcomes included pre‐ to posttreatment change in marginal reflex distance (MRD1) after treatment with topical oxymetazoline, and mean difference (pre‐to‐posttreatment) in MRD1 versus control. Results Five articles included data from 458 patients for analysis. Meta‐analysis demonstrated significant improvement in MRD1 measurements posttreatment with oxymetazoline (1.40 mm; 95% confidence interval, CI [0.41 mm, 2.40 mm]). In addition, when compared to controls, patients treated with oxymetazoline demonstrated greater increase in MRD1 values (0.83 mm; 95% CI [0.10 mm, 1.55 mmm]). Heterogeneity, measured by I 2 statistic, was high in all studies (85%–95%). Conclusion The use of oxymetazoline 0.1% ophthalmic solution significantly improves MRD1 in patients with acquired blepharoptosis. Further studies comparing this treatment in other etiologies of acquired blepharoptosis should be conducted. Laryngoscope , 2024

Abstract licence: CC BY-NC

BACKGROUND AND OBJECTIVES: Rosacea is a chronic inflammatory condition affecting the central face. While laser and energy-based devices (EBDs) are commonly used for managing vascular symptoms, comprehensive comparisons between systems are limited. This study aims to evaluate and compare the efficacy and safety of lasers and EBDs for rosacea through a systematic review and network meta-analysis (NMA). METHODS: Randomized controlled trials (RCTs) were identified from MEDLINE, CENTRAL, and Web of Science, with additional searches for ongoing trials. Primary outcomes included patient satisfaction, improvements in erythema and telangiectasia, and long-term adverse events (AEs). Risk of bias (RoB) and publication bias were also assessed. RESULTS: 25 RCTs were included for qualitative analysis, and subsets contributed to the NMAs. Most studies exhibited unclear or high risk of bias, with a slight publication bias observed. Radiofrequency microneedling was more effective than pulsed dye laser (PDL) in terms of patient satisfaction (MD -1.32; 95 % CI -1.89 to -0.76) and erythema (MD -1.44; 95 % CI -1.96 to -0.91). The combination of oxymetazoline and PDL appeared superior for telangiectasia (MD -0.58; 95 % CI -1.03 to -0.14). AEs and discontinuation rates were comparable across treatments.

Abstract licence: CC BY

BACKGROUND: Facial persistent erythema is recognized as difficult feature to treat in rosacea. Topical Oxymetazoline cream 1% has been used to treat persistent facial erythema in rosacea patients for some years. OBJECTIVE: To quantitatively synthesize the benefits and harms of Oxymetazoline cream 1% in real-world clinical management of treatment response and adverse events. METHODS: The clinical researches before June 1, 2022 published on online databases including PubMed, Web of Science, Embase and Cochrane Library were meta-analyzed. RESULTS: A total of 2298 participants were included, and the improvement rate of two-grade Clinician Erythema Assessment score (CEA) and Subject Self-Assessment for rosacea facial redness score (SSA) in Oxymetazoline group was 38% (95%CI 28-48) and 25% (95%CI 22-27), respectively, at the 4th week of the dosing. The comprehensive rate of treatment-related TEAEs in Oxymetazoline group was 7% (95%CI 5-8). The rate of stinging/burning was 15% (95%CI 10-19), pruritus was 15% (95%CI 9-22), dryness was 23% (95%CI 18-28), and scaling was 17% (95%CI 12-22) in analysis of dermal tolerability. And topical Oxymetazoline cream 1.0% presented a very low rebound rate of erythema (1%, 95%CI 0-2). CONCLUSIONS: These real-world data on Oxymetazoline cream 1% in rosacea-associated erythema may help making clinic decision and informing treatment expectations, and more clinic trials on longer-term dosing or the combination treatment with oral medication and energy-based therapy are worth exploring.

Abstract licence: CC BY

Background: Considering the high prevalence of tonsillectomy in children and concerns of postoperative management, this study was conducted with the aim of evaluating the effects of oxymetazoline on bleeding, cough, and sore throat in children undergoing tonsillectomy. Materials and Methods: The current double-blind clinical trial study was conducted on 88 tonsillectomy candidate patients. These patients were randomly divided into two groups. In the first group, oxymetazoline 0.05% nasal spray (OXY group) and in the second group, distilled water spray (Control group) was prescribed as one puff in each nostril immediately after anesthesia induction., the nasal spray was prescribed again in both nostrils at 12 h after tonsillectomy. Then the hemodynamic parameters, post-tonsillectomy hemorrhage (PTH) and sore throat were evaluated. Results: The mean of the sore throat of children was not significantly different between the two groups in any of the follow-up times ( P value >0.05). PTH in recovery and in the ward in the OXY group with the mean of 57.60 ± 71.82 ml and 22.11 ± 22.50 ml, respectively, was significantly lower than the control group (83.50 ± 113.64 ml and 27.52 ± 35.11 ml) ( P value < 0.05). Also, the frequency of cough in the ward in the OXY group with 27.3% was significantly lower than the control group with 56.8% ( P value = 0.005). Conclusion: Regarding the results of the present study, sore throat and hemodynamic parameters did not change significantly with the administration of oxymetazoline. But this drug has played a significant role in reducing PTH and cough in children.

Abstract licence: CC BY-NC-SA

BACKGROUND: The demand for nonsurgical facial rejuvenation options is growing, yet the periorbital region remains an area of relative unmet need. This review explores nonsurgical options for facial rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating age-related blepharoptosis as part of periorbital rejuvenation. METHODS: Advisors experienced in facial rejuvenation met to discuss existing literature on the upper face and periorbital rejuvenation and the role of oxymetazoline hydrochloride ophthalmic solution, 0.1%, in treating facial aging. RESULTS: An array of nonsurgical options exist to address the signs of aging, including minimally invasive treatments, such as botulinum toxin injections and dermal fillers, and noninvasive therapy, such as lasers, chemical peels, and microdermabrasion. However, treating age-related ptosis in periorbital rejuvenation is mainly addressed surgically. The newly approved α-adrenergic receptor agonist oxymetazoline hydrochloride ophthalmic solution, 0.1%, provides a novel non-interventional approach to blepharoptosis. CONCLUSIONS: Facial rejuvenation is highly sought-after in this post-pandemic era. Each nonsurgical treatment option has its advantages and drawbacks. A patient-centered approach is necessary to select the appropriate procedure considering the patient's concerns and aesthetic sensibilities. The eyes are an area of primary concern for patients, yet surgery is the gold standard for treating ptosis. Oxymetazoline hydrochloride ophthalmic solution, 0.1%, is a safe and effective nonsurgical treatment for blepharoptosis.

Abstract licence: CC BY

Conjunctival hyperemia is one of the most frequent ophthalmologic presentations and may adversely affect quality of life due to associated discomfort and aesthetic concerns. In many countries, the prevalence of noninfectious conjunctival hyperemia is increasing due to lifestyle factors and the shift to technology-based employment. Management of noninfectious conjunctival hyperemia is typically aimed at addressing the underlying cause while alleviating signs and symptoms. However, an underlying cause might not be identified, treatment may not immediately reduce redness, or residual redness might persist. Topical treatment options include lubricants, decongestants, antihistamines/mast cell stabilizers, and anti-inflammatory drugs. Among these, ocular decongestants provide effective short-term relief, but the use of α1- (phenylephrine, tetrahydrozoline) or mixed α1/α2- (naphazoline, oxymetazoline) adrenergic receptor agonists is associated with tachyphylaxis and rebound redness. A highly selective α2- adrenergic receptor agonist (brimonidine 0.025%) reduces ocular redness without evidence of tachyphylaxis over 29 days and with minimal rebound redness upon discontinuation; however, longer-term effectiveness has not been evaluated. Other unmet needs pertain to the management of noninfectious conjunctival hyperemia as an aesthetic issue and the need to educate patients about the risks of surgical eye-whitening procedures and national recalls. Region- or country-specific unmet needs include a lack of awareness of the need for clinical assessment and appropriate treatment of ocular redness. While many cases of noninfectious conjunctival hyperemia can be self-treated, unmet needs remain with respect to access to care and patient awareness/knowledge of safe and appropriate treatment options and the importance of clinical consultation. The development of management guidelines specific to noninfectious conjunctival hyperemia is warranted to address patients' clinical and aesthetic concerns.

Abstract licence: CC BY-NC